ReviewTherapeutic advances in urology2016
What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence.
Review in Therapeutic advances in urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Dendritic Cell Immunotherapy for Solid Tumors: Advances in Translational Research and Clinical Application.Current issues in molecular biology · 2025Review
- 7-Molecules (Basel, Switzerland) · 2019Article
- Delivery strategies of cancer immunotherapy: recent advances and future perspectives.Journal of hematology & oncology · 2019Review
- A multi-targeting natural compound with growth inhibitory and anti-angiogenic properties re-sensitizes chemotherapy resistant cancer.PloS one · 2019Article
- Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy.Molecular therapy oncolytics · 2018Article
- Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil.Journal of translational medicine · 2018Article
- Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?Current opinion in urology · 2017Review
- Treatment sequence in castration-resistant prostate cancer: A retrospective study in the new anti-androgen era.Molecular and clinical oncology · 2017Article
- Advancing Immune and Cell-Based Therapies Through Imaging.Molecular imaging and biology · 2017Review
- Adverse Events of Oncologic Immunotherapy and Their Management.Asia-Pacific journal of oncology nursingReview
- Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most common cancer in men and the second most deadly. About one-third of patients with prostate cancer will develop metastatic disease. We discuss the six United States Food and Drug Administration (FDA) approved treatments for metastatic castrate-resistant prostate cancer (mCRPC) with a strong focus on sipuleucel-T. Sipuleucel-T is the first immunotherapy shown to improve survival in asymptomatic or minimally-symptomatic mCRPC. Herein, we discuss the proposed mechanism of sipuleucel-T and its synthesis. We describe in detail the three randomized controlled trials (RTCs) that led to its approval. We also compiled the newest research regarding use of sipuleucel-T with other agents and in different patient populations. Finally, we discuss the current ongoing trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.